Skip to main content

Alnylam Wraps Up Enrollment in RSV Drug Trial

Premium

Alnylam Pharmaceuticals announced this week that it has completed enrollment in a phase IIb study of its investigational respiratory syncytial virus therapy ALN-RSV01.

The trial is a multi-center, randomized, double-blind, placebo-controlled study in RSV-infected lung transplant patients, according to the company. It is being conducted at lung-transplant centers in six countries. As previously disclosed, data are expected to be reported mid-2012 (GSN 11/3/2011).

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.